Drug Profile
Research programme: metabotropic glutamate receptor 5 antagonists - Roche/Seaside Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Seaside Therapeutics
- Developer Roche; Seaside Therapeutics
- Class
- Mechanism of Action Metabotropic glutamate receptor 5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autistic disorder; Fragile X syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autistic-disorder in USA
- 16 Jul 2016 No recent reports of development identified for research development in Fragile-X-syndrome in USA
- 20 Jun 2012 Early research in Autistic disorder in USA (unspecified route)